New rnai company, page-2

Interesting but their website does not talk of treatment candidates nor of approvals or upcoming trials. What of their products? The website focus is on recruiting.
They appear to have 2 products both preclinical.

QR-010

	Column 1	Column 2
1	Publication number	WO2014011053 A1
2	Publication type	Application
3	Application number	PCT/NL2013/050534
4	Publication date	Jan 16, 2014
5	Filing date	Jul 12, 2013
6	Priority date	Jul 12, 2012
7	Inventors	BOER Daniel Anton DE, Tita RITSEMA
8	Applicant	Proqr Therapeutics B.V.
9	Export Citation	BiBTeX, EndNote, RefMan
10	Patent Citations (9), Non-Patent Citations (43), Classifications (6), Legal Events (2)

	Column 1	Column 2
1	Company	ProQR Therapeutics B.V.
2	Description	RNA-based oligonucleotide
3	Molecular Target
4	Mechanism of Action	Antisense therapy
5	Therapeutic Modality	Nucleic acid: Linear RNA: Antisense

	Column 1	Column 2
1	Latest Stage of Development	Preclinical
2	Standard Indication	Cystic fibrosis (CF)
3	Indication Details	Treat cystic fibrosis (CF)
4	Regulatory Designation	U.S. - Orphan Drug (Treat cystic fibrosis (CF));EU - Orphan Drug (Treat cystic fibrosis (CF))
5	Partner

QR-110
Did not find any patent information on this one but did find competition
http://www.thestreet.com/story/1287...gene-therapy-stocks-tackling-eye-disease.html

	Column 1	Column 2	Column 3	Column 4	Column 5	Column 6
1	General Information Column 1Company

[/table]| ProQR Therapeutics B.V.Description| Molecular Target| Centrosomal protein 290kDa (CEP290)Mechanism of Action| Therapeutic Modality|  [/table]

	Column 1	Column 2	Column 3	Column 4	Column 5	Column 6
1	Latest Stage of Development	PreclinicalStandard Indication	BlindnessIndication Details	Treat Leber's congenital amaurosis (LCA)Regulatory Designation	Partner

[/table]
[/table]
It will be interesting to see how the market welcomes them.